Furthermore, the hepatoprotective effect of
1 against APAP-induced hepatotoxicity in HepG2 cells and a mice model were evaluated. All animal experiments were approved by the Animal Experimentation Ethics Committee of Chinese Academy of Medical Sciences in complete compliance with the guidelines of Institutional Animal Care and Use Committees of Chinese Academy of Medical Sciences (Beijing, China). In the
in vitro experiment,
1 could alleviate damage to the hepatocyte induced by APAP in HepG2 cells. As shown in
Fig. 5A, the viability of HepG2 cells was significantly decreased by 46.21% after exposure to 10 mmol/L APAP. However, cells were pretreated with
1 significantly against APAP-induced cell damage, and increased cells viability to 77.50%. The flow cytometry results showed that
1 inhibited cell apoptosis and the intracellular reactive oxygen species (ROS) levels in APAP-induced HepG2 cells in a dose-dependent manner (
Figs. 6 and
7). The down-regulation expression of oxidative stress proteins, heme oxygenase-
1 (HO-
1), NAD(P)H dehydrogenase quinone
1 (NQO-
1), and catalytic or modify subunit of glutamate-cysteine ligase (GCLC/GCLM), was markedly reversed by the pretreatment of
1. To assess the protective effects of
1 in vivo, a mice model with acute liver injury (ALI) induced by APAP administration was established. As shown in
Fig. 7, the levels of serum alanine transaminase (ALT) and aspartate transaminase (AST) in the APAP group sharply increased to 1429.22 ± 82.84 and 1455.47 ± 97.41 U/L, respectively, compared with 36.17 ± 2.96 and 78.37 ± 4.56 U/L in the control group. Pretreatment with
1 (10, 20 and 30 mg/kg) significantly attenuated APAP-induced elevation of ALT and AST levels in a dose-dependent manner. ALT activities decreased to 298.95 ± 20.26, 120.75 ± 13.42, and 66.35 ± 11.03 U/L when pretreated with 10, 20, and 30 mg/kg of
1, respectively, and AST activities decreased to 608.55 ± 29.90, 224.95 ± 23.42 and 169.70 ± 8.67 U/L, respectively. In addition, the APAP-induced hepatic glutathione (GSH) and superoxide dismutase (SOD) depletion (2.80 ± 0.62 µmol/g protein and 192.39 ± 8.23 U/mg protein, respectively) was significantly prevented by pretreatment with
1 at 30 mg/kg (GSH levels increased to 7.16 ± 0.31 µmol/g protein and SOD levels increased to 291.56 ± 13.01 U/mg protein). An evaluation of liver provided further evidence that pretreatment with
1 reversed APAP-induced hepatocellular necrosis, hemorrhaging, and infiltration of inflammatory cells (
Fig. 8).